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Abstract
CD8+ T cells specific to caspase-cleaved antigens derived from apoptotic T cells (apoptotic epi-
topes) represent a principal player in chronic immune activation, which is known to amplify immu-
nopathology in various inflammatory diseases. The purpose of the present study was to
investigate the relationship involving these autoreactive T cells, the rheumatoid arthritis immuno-
pathology, and the response to tumor necrosis factor-α inhibitor therapy. The frequency of auto-
reactive CD8+ T cells specific to various apoptotic epitopes, as detected by both enzyme-linked
immunospot assay and dextramers of major histocompatibility complex class I molecules com-
plexed with relevant apoptotic epitopes, was longitudinally analyzed in the peripheral blood of
rheumatoid arthritis patients whowere submitted to etanercept treatment (or other tumor necrosis
factor inhibitors as a control). The percentage of apoptotic epitope-specific CD8+ T cells was sig-
nificantly higher in rheumatoid arthritis patients than in healthy donors, and correlated with the
disease activity. More important, it was significantly more elevated in responders to tumor necro-
sis factor-α inhibitor therapy than in non-responders before the start of therapy; it significantly
dropped only in the former following therapy. These data indicate that apoptotic epitope-specific
CD8+ T cells may be involved in rheumatoid arthritis immunopathology through the production of
inflammatory cytokines and that theymay potentially represent a predictive biomarker of re-
sponse to tumor necrosis factor-α inhibitor therapy to validate in a larger cohort of patients.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease occurring in 0.5% to 1.0% of the adult
population worldwide, principally characterized by inflammatory polyarthritis with localized
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inflammation of joint synovial tissue and progressive destruction of bone and cartilage [1].
Complex interactions among genetic, immunologic, and environmental factors play a role in
RA development [1–8].
Both pro-inflammatory innate (e.g., dendritic cells [DCs], macrophages, and neutrophils) and
adaptive (e.g., T helper [Th]1, Th17, CD8 T, and B) cells, which can organize into discrete lym-
phoid aggregates with germinal centers in RA, are strongly involved in initiating and maintaining
the disease through the production of autoantibodies and many cytokines that act both in series
and in parallel, meaning cascades of action and redundancy [1,2,9–14]. Tumor necrosis factor
(TNF)-α interleukin (IL)-1 family of cytokines (IL-1α, IL-1β, IL-18, and IL-33), and IL-6, particu-
larly those produced by activated macrophages (predominantly M1macrophages, the major effec-
tors of synovitis), exert pro-inflammatory effects mediated by the induction of other pro-
inflammatory cytokines, metalloproteinases, free radicals, serine proteases, and aggrecanases [1,2].
As a consequence of the activated inflammatory pathways in the inflamed synovium of RA
patients, an enormous number of apoptotic cells results from the rapid turnover of effector T
cells undergoing apoptosis after performing their functions. This may further amplify immu-
nopathology [15]. In previous studies, we demonstrated that the proteome of apoptotic T cells
includes prominent caspase-cleaved cellular proteins (i.e., fragments cleaved from long-lived
proteins that are anchored to cellular structures), such as actin cytoplasmic 1 [(ACTB]), hetero-
geneous nuclear ribonucleoprotein [(ROK]), lamin B1 [(LAM1]), non-muscle myosin heavy
chain 9 [(MYH9]), vimentin [(VIME]), proteasome component C2 [(PSA1)], rho GDP dissoci-
ation inhibitor 2 (GDIS), and 60S acidic ribosomal protein P2 (RLA] [16]. In particular, upon
phagocytosis of apoptotic T cells by dendritic cells (DCs), caspases within apoptotic cells can
cleave fragments from these long-lived proteins, which are then efficiently processed by DCs
that ultimately cross-present a high proportion of distinct epitopes in these fragments (apopto-
tic epitopes [AEs]) via the classical major hisotocompatibility complex (MHC) class I pathway
to a wide repertoire of autoreactive CD8+ T cells [16–19]. Importantly, apoptotic cells derived
from activated T cells retain the expression of CD40 ligand (CD40L) and, in contrast to
CD40L- apoptotic cells (e.g., those derived from epithelial cells), can condition CD40+ DCs to
acquire high capacities to prime or cross-prime autoreactive T cells specific to apoptotic T cell-
derived epitopes [20,21]. This finding is supported by the evidence that the proportion of AE-
specific CD8+ T cells correlated with the proportion of circulating apoptotic CD4+ T cells in
vivo and with the disease progression in chronic human immunodeficiency virus (HIV) or
acute hepatitis C virus (HCV) infections [16,22]. Research has suggested that the emergence
and the maintenance of these responses contribute to establishing the phenomenon of chronic
immune activation (CIA) and, ultimately, in amplifying the immunopathology in autoimmune
diseases, such as multiple sclerosis (MS), through their capacity to produce high levels of in-
flammatory cytokines [23].
The proof of principle of the pathogenic role of the panoply of cytokines in RA derives from
the observation that the administration of available biological therapeutics (subsumed as bio-
logical originator [bo] disease-modifying antirheumatic drugs [DMARDs]), blocking tumor
necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, or inflixi-
mab), the interleukin (IL)-6 receptor (IL-6R) (tocilizumab), or IL-1 (anakinra), is associated
with clinical improvement [24]. Similarly, research has shown that the administration of
monoclonal antibodies (mAbs) against activated B cells (rituximab) or the T cell costimulation
inhibitor (abatacept) results in parallel clinical improvement [24].
The aims of the present study are to ascertain if CD8+ T cells specific for AEs are prominent
in RA patients, to distinguish which of them is associated with disease severity, and to deter-
mine if they have the potentiality to predict which patients might (or might not) benefit from
therapy with TNF-α inhibitors.
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Materials and Methods
Study Population
Sixteen selected HLA-A2+ biologic-naïve RA (according to the 1987 American College of
Rheumatology [ACR] criteria) patients (female/male [F/M] = 15/1; median age 53 years range
36–69 years; mean disease duration 96.6 months range 6–240 months) who had shown an un-
satisfactory response to conventional DMARDs including methotrexate (associated or not as-
sociated with other anti-inflammatory/immunosuppressive drugs) and who submitted to
subsequent treatment with etanercept were included in the study (S1 Table). Each patient was
given a standard dose of 50 mg etanercept per week subcutaneously and followed for clinical
parameters. Clinical response was set in the present study as an improvement of the disease ac-
tivity score using 28 joint counts (DAS28)> 0.6 after 6 months of therapy in accordance with
the European League Against Rheumatism (EULAR) response criteria [25]. Of the 16 patients,
9 were responders (Rs) and 7 were non-responders (NRs) (S1 Table and S1 Fig). As a control,
six RA patients (female/male [F/M] = 6/0; median age 60.5 years range 48–70 years; mean dis-
ease duration 165 months range 24–288 months) submitted to adalimumab were also enrolled:
2 resulted Rs and 4 NRs (S2 Fig). No difference was detected between Rs and NRs in terms of
duration of disease, disease activity (as calculated by DAS28-erythrocyte sedimentation rate
[ESR] or DAS28-C-reactive protein [CRP], and serum levels of ACPA or rheumatoid factor
(RF) before the start of therapy (S1 Table). Twenty-four HLA-A2+ healthy donors (HDs)
matched for sex and age with patients were also included. The study was conducted in accor-
dance with the principles expressed in the Declaration of Helsinki. The study protocol was ap-
proved by the relevant research ethics committee of Sapienza Università di Roma- Azienda
Policlinico Umberto I di Roma (n. 3202/15.05.2014). All patients and controls gave written
informed consent.
Synthetic Peptides
Ninety-one synthetic peptides (nonamers or decamers) were prepared according to the se-
quence of caspase-cleaved proteins (ACTB, ROK, LAM1, MYH9, GDIS, VIME, PSA1, RLA)
that had been identified by the proteomic analyses of apoptotic T cells, as previously described
(S2–S4 Tables) [16]. All the peptides were synthesized and selected for their capacity to bind
the HLA-A2 molecule [16,26].
Cell Preparations
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient method.
Spontaneous apoptosis of T cells from patients was determined by staining fresh PBMCs with
fluorescein isothiocyanate (FITC)-labeled Annexin V (BioLegend), propidium iodide (PI)
(BioLegend), and allophycocyanin (APC)-labeled anti-CD3 mAb (BioLegend).
Enzyme-Linked Immunospot Assay
Following stimulation with 12 independent pools of AEs (S2–S4 Tables), PBMCs were tested by
enzyme-linked immunospot (ELISPOT) assay [16,22]. Briefly, 96-well millimeter high-affinity
plates (Millipore, Bedford, MA) were coated with 10 μg/ml of capture mAb against interferon
(IFN)-γ (BD Bioscience) at 4°C overnight. Plates were blocked for 2 h with blocking solution
(phosphate-buffered saline [PBS] containing 2% bovine serum albumin [BSA]). A total of 1 × 105
PBMCs were added to each well and stimulated for 18 h with peptides. Biotinylated anti-IFN-γ di-
luted to 5 μg/mlin blocking solution was added and incubated for 2 h in 5% CO2 at 37°C. Plates
were washed, incubated with alkaline phosphatase (AKP)-streptavidin (BD Bioscience), and
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developed with SIGMAFAST BCIP/NBT (Sigma). The reaction was stopped by rinsing the plates
with distilled water. Each well was then examined for positive dots. The number of dots in each
well was counted with an ELISPOT reader system (AELVIS reader system). IFN-γ-secreting cells
were expressed as IFN-γ spots per 1 × 106 cells. The IFN-γ spot values were subtracted from the
background, which was below 10 IFN-γ spots in 1 x 106 cells for each test.
Monoclonal Antibody and Dextramer Staining
PBMCs were incubated with APC-labeled—HLA-A0201 dextramers complexed to MYH9478-486
(QLFNHTMFI), MYH9741-749 (VLMIKALEL), VIME78-87 (LLQDSVDFSL), VIME225-233
(SLQEEIAFL), or ACTB266-274 (FLGMESCGI) peptides (Immudex, Copenhagen, Denmark). The
incubation was performed in fluorescence-activated cell sorting (FACS) buffer (PBS containing
2% human AB serum) at room temperature for 10 min, followed by washing and further surface
staining with FITC-labeled mAb to CD8 (eBioscience), phycoerythrin-cyanine (PeCy)7-labeled
mAb to program death (PD)-1 (eBioscience), AlexaFluor700-labeled mAb to CD69, PE-C-
F594-labeled mAb to HLA-DR, and a cocktail of labeled mAbs and labeled reagents (APC-Cy7-la-
beled mAbs to CD4, CD14, CD16, CD19, and CD56 [BioLegend]) and Fixable Viability Dye
eFluor 780 (eBioscience) (dump channel) for 20 min at 4°C. Dextramer+ cells were analyzed with-
in a CD8+ cell gate, whereas CD69+, HLA-DR+, or PD-1+ cells were analyzed within dextra-
mer+CD8+ cells after the exclusion of B cells, monocytes, natural killer T (NKT) cells, NK cells,
and CD4+ T cells (dump channel). Cells were acquired with LSRFortessa cytometer (Becton Dick-
inson) and analyzed with FlowJo software version 7.5.5 (Tree Star, San Carlos, CA).
Intracellular Cytokine Staining
Cytokine production was analyzed by intracellular staining (ICS) assay. PBMCs were incubated
with or without the relevant peptides (20 μg/ml) plus anti-CD28 mAb (4 μg/ml) (BD Biosci-
ences) and the Protein Transport Inhibitor Cocktail (Brefeldin A and Monensin; eBioscience),
or with the Cell Stimulation Cocktail (phorbol 12-myristate 13-acetate [PMA], ionomycin, bre-
feldin A, and monensin; eBioscience) as a positive control, for 18 h at 37°C [16,22]. Cells were
washed and then stained with APC-labeled—HLA-A0201 dextramers complexed to corre-
sponding peptides, PeCy7-labeled mAb to CD8 (BioLegend), and the dump channel reagents.
Cells were fixed and permeabilized using the BD Cytofix/Cytoperm Fixation/Permeabilization
Solution Kit (BD Biosciences) at 4°C for 20 min, rewashed with the BD Perm/Wash buffer (BD
Biosciences), and stained with different combinations of AlexaFluor700-labeled IL-17A (Bio-
Legend) and FITC-labeled anti-IFN-γ (BioLegend) for 20 min at 4°C. Cells were washed, ac-
quired with the LSRFortessa cytometer, and analyzed with FlowJo software. IL-17, IFN-γ or
IL-17/IFN-γ producing cells were analyzed in CD8+dextramer+ cells after exclusion of B cells,
monocytes, NKT cells, NK cells, and CD4+ T cells (dump channel).
Statistical Analyses
The collected data underwent statistical analysis with GraphPad Prism version 4 software
(GraphPad Software). Comparisons between HDs and patients, comparisons in patients at dif-
ferent times, correlations between the different tests performed, and correlations between tests
and clinical data were analyzed with the Mann-Whitney test, the Wilcoxon matched pairs test,
linear regression, and the Spearman’s correlation, respectively. The significance threshold was
set at P = 0.05. Receiver operating characteristic (ROC) analysis was performed to assess the
predictive power of AE-specific CD8+ T cells. The area under the ROC curve (AUC) was calcu-
lated along with 95% confidence intervals (CI). In our study, the AUC value indicates the abili-
ty of dextramer+ T cells to distinguish Rs and NRs.
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Results
Multispecific CD8+ T Cell Responses to AEs
Initially, we analyzed longitudinally the effector responses based on the capacity of freshly iso-
lated CD8+ T cells from either 12 (of the 16) HLA-A2+ patients submitted to etanercept or 24
HDs to form IFN-γ spots (in an ELISPOT assay) within 4 h to 6 h of contact with 12 pools con-
taining a total of 90 synthetic HLA-A2-binding apoptotic peptides (S2–S4 Tables) [16,22].
These peptides (nonamers or decamers) were prepared according to the sequence of caspase-
cleaved proteins (ACTB, ROK, LAM1, MYH9, GDIS, VIME, PSA1, RLA) that had been identi-
fied by the proteomic analyses of apoptotic T cells, as previously described [16]. All the pep-
tides were synthesized and selected for their capacity to bind the HLA-A2 molecule (S2–S4
Tables) [16,26]. Therefore, we defined these CD8+ cells as effector memory T (TEM) cells on
the basis of their capacity to perform their effector functions promptly within a few hours of
antigenic stimulus. Each peptide pool was tested in triplicate. The synthetic peptides used were
prepared according to the sequence of caspase-cleaved proteins that had been previously iden-
tified by the proteomic analyses of apoptotic T cells (e.g., fragments of ACTB, ROK, LAM1,
MYH9, GDIS, VIME, PSA1, and RLA) [16,22]. We found that the responses to AEs by IFN-
γ+CD8+ TEM cells were significantly higher and wider in patients than in HDs (Fig 1).
In particular, the median number of IFN-γ spots formed by CD8+ TEM cells from all RA
patients or HDs in response to the single peptide pool (responsiveness) (Fig 1A) and the sum
of IFN-γ spots formed in response to the total peptide repertoire by a single patient or HD
(magnitude) (Fig 1B) were significantly higher in RA patients than in HDs. The HLA-
restriction of these responses was demonstrated both by blocking responses with an appropri-
ate anti-class I mAb and by determining that no response was observed in HLA-A2-patients
(data not shown). No correlation was found between the ELISPOT responses to AEs and the
disease activity, as calculated by both DAS28-ESR and DAS28-CRP (data not shown). In addi-
tion, no difference in the AE repertoire recognized by IFN-γ+CD8+ TEM cells was observed be-
tween Rs and NRs at the time point tested before the start of therapy (time 0) (Fig 1C).
AE-Specific CD8+ T Cells as Detected by Dextramers Predict the Effect
of TNF-α Inhibitor Therapy
To explore the possibility that the frequencies of CD8+ T cells specific to AE, as detected by
ELISPOT assay, did not differ between Rs and NRs (Fig 1A) because our ELISPOT system
identified only IFN-γ+ cells, we conducted further testing. In particular, we used the class I
molecule multimer technology, thereby allowing the entire AE-specific CD8+ T cell population
to be counted with the same epitope specificity, irrespective of their differentiation phase, as
well as T cells with an “exhaustion phenotype,” representing the reducing capacity of cells to
perform effector functions [27]. We enumerated AE-specific CD8+ T cells in the peripheral
blood of 15 HLA-A2+ RA patients submitted to etanercept (of whom 9 would be Rs and 6
would be NRs) by using dextramers of HLA-A0201 molecules complexed to ACTB266-274,
MYH9478-486, MYH9741-749, VIME78-87, or VIME225-233 peptides (Fig 2).
Control dextramers complexed to a non-natural irrelevant peptide were unable to stain
CD8+ T cells in all samples tested (data not shown). All patients presented frequencies of pe-
ripheral dextramer+CD8+ T cells significantly higher than HDs, in terms of both responsive-
ness and magnitude (Fig 2A and 2B). Amazingly, the total frequencies of AE-specific CD8+ T
cells, as detected by dextramers, were significantly higher in Rs than in NRs to etanercept thera-
py at time 0 (Fig 2C). Similarly, the AE-specific CD8+ T cells frequency was significantly higher
in Rs than in NRs to adalimumab therapy at time 0 (S2 Fig) To evaluate the discriminatory
Apoptosis-Induced T Cells Predict Response to TNF Inhibitor Therapy
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accuracy of AE-specific CD8+ T cells, ROC analysis was performed. When a comparison was
made between Rs and NRs, the AUC was 0.82 (95% CI = 0.722–0.925, P< 0.0001) (Fig 2D).
By contrast, no differences in DAS28-ESR, DAS28-CRP, age, disease duration, and presence of
ACPAs between Rs and NRs were observed at time 0 (S1 Table and S3 Fig). The percentage of
early apoptotic T cells (as detected by Annexin V staining) circulating in PBMCs was signifi-
cantly more elevated in total patients than in HDs (Fig 3A and 3B), as well as (more important)
significantly more elevated in Rs than in NRs (Fig 3C).
Notably, it directly correlated with the frequency of AE-specific CD8+ T cells (Fig 3D), sug-
gesting a possible cause-and-effect relationship between the two events. A significant propor-
tion of these AE-specific CD8+ T cells expressed late activation markers (e.g., HLA-DR and
PD-1), indicating that they are experienced T cells (Fig 4A and 4B). However, in contrast to the
total AE-specific CD8+ T cells that were significantly higher in Rs (see Fig 2), the experienced
AE-specific CD8+ T cells (and, in particular, those expressing the PD-1 exhaustion marker)
were represented more in NRs than in Rs (Fig 4A and 4B).
Importantly, PD-1 expression inversely correlated with the frequencies of the total AE-specific
CD8+ T cells (Fig 4C), a result suggesting that the inhibitory PD-1 molecule plays a role in tem-
pering T cell survival/expansion, particularly in NRs showing the frequencies of these cells to be
significantly lower than in Rs at time 0 (see Fig 2). To validate the antigen specificity of AE-specific
Fig 1. CD8+ T cell multispecificity to AEs in HDs and RA patients (A-C). (A) Mean number of IFN-γ spots formed by fresh CD8+ TEM cells (by ELISPOT
assay) in response to 12 pools of AEs (see S2–S4 Tables) in 12 HLA-A2+ patients with RA or 24 HLA-A2+ HDs. (B) Sum of IFN-γ spots formed by fresh CD8+
TEM cells in response to all pools (see S2–S4 Tables) of AEs in the single patient or HD. (C) Sum of IFN-γ spots formed by fresh CD8+ TEM cells in response
to all pools (see S2–S4 Tables) of AEs in the single R, NR, or HD. Analyses were performed at time 0 (before the start of therapy). Statistical analysis was
performed with the Mann-Whitney test. *P < 0.01; **P < 0.001; ***P < 0.0001. ns = not significant. RLA2 = 60S acidic ribosomal protein P2;
PSA1 = proteasome component C2; VIME = vimentin; GDIS = rho GDP dissociation inhibitor 2; Myh9 = non-muscle myosin; LAM1 = Iamin B1;
ROK = heterogeneous nuclear ribonucleoprotein K; ACT B = actin cytoplasmic 1.
doi:10.1371/journal.pone.0128607.g001
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(dextramer+) CD8+ T cells, we analyzed their capacity to produce inflammatory cytokines (IFN-γ,
IL-17) within a few hours of contact with the relevant peptides and optimal concentrations of
anti-CD28 mAb, which served as a surrogate costimulatory signal. Undetectable cytokine produc-
tion was observed when AE-specific CD8+dextramer+ T cells of 20 HLA-A2+ HDs were stimulat-
ed with this procedure (data not shown). Notably, AE-specific CD8+dextramer+ T cells produced
moderate amounts of IFN-γ or IL-17 in response to the relevant epitopes ex vivo, providing evi-
dence that they were effectively antigen-specific TEM cells (Fig 5).
Although the level of these responses was not significantly different between Rs and NRs at
time 0 (Fig 5A and 5B), they were inversely correlated with the percentage of AE-specific CD8+
T cells expressing PD-1 (Fig 5C), which were represented more in NRs than in Rs (see Fig 4B).
Fig 2. AE-specific CD8+ T cells predict RA patients who will (or will not) benefit from etanercept therapy (A-D). (A) Representative flow cytometry
analysis of dextramer+CD8+ T cells specific to AE in an RA patient and an HD. Zebra plot analyses show the percentage of dextramer+CD8+ cells. (B)
Percentage of dextramer+CD8+ cells in 14 HDs and 15 patients (each symbol represents the percentage of a single dextramer+CD8+ cell population) (left
graph); sum of the percentages of all dextramer+CD8+ T cells detected in the single HD or patient (each symbol represents the sum of dextramer
percentages in a single individual) (right graph). (C) Percentage of dextramer+CD8+ cells in 14 HDs, 9 Rs to etanercept, and 6 NRs (each symbol represents
the percentage of a single dextramer+CD8+ cell population) (left graph); sum of the percentages of all dextramer+CD8+ T cells detected in the single HD, R,
and NR (each symbol represents the sum of dextramer percentages in a single individual) (right graph). Analyses were performed at time 0 (before the start
of therapy). Statistical analysis was performed with the Mann-Whitney test. **P < 0.001; ***P < 0.0001. (D) ROC curve analyses for R and NR patients.
AUC = area under receiver operating characteristic curve. * = predictive value of positive test. # = predictive value of negative test.
doi:10.1371/journal.pone.0128607.g002
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Follow-Up of AE-Specific CD8+ T Cells in RA Patients Treated with TNF-
α Inhibitors
Time course analyses were then performed in patients treated with TNF-α inhibitors. They re-
vealed that ELISPOT responses, which were equally represented in Rs and NRs at time 0 (see
Fig 1), significantly declined only in Rs (S4 Fig); however, they did not correlate with the de-
cline of disease activity (data not shown). This finding, together with the finding that the IFN-
γ+ ELISPOT assay did not display any predictive value (no difference was shown between Rs
and NRs at time 0 [see Fig 1]), led us to monitor the frequencies of all the AE-specific CD8+ T
cell populations with the same epitope specificity, irrespective of their differentiation phase
(dextramer+ cells), so as to verify if they may provide more sensitive information during the
time course analyses. The frequencies of AE-specific (dextramer+) CD8+ T cells (predicting the
response to TNF-α inhibitor therapy [see Fig 2]) dropped in a significant fashion since the first
month of therapy in Rs, but not in NRs (Fig 6A and 6B), and in a manner considerably more
sensitive than that observed in the ELISPOT assay.
It is important to note that the AE-specific CD8+ T cell frequency in Rs after 1 month of
therapy decreased at a level significantly lower than the corresponding frequencies in NRs (Fig
6A and 6B). Importantly, the decrease of the AE-specific CD8+ T cells in Rs, but not in NRs
(not shown), was related to the reduction of clinical parameters (e.g., DAS28-ESR) (Fig 6C and
Fig 3. AE-specific CD8+ T cells correlate with circulating apoptotic T cells in RA patients (A-D). (A) Representative flow cytometry analysis of double-
stained Annexin V/PI+ cells in CD3+ T cells from an HD or an RA patient. The percentage of Annexin V+/PI-cells is indicated in the appropriate quadrant. (B)
Percentage of circulating early (Annexin V+/PI-) apoptotic T cells in 16 HDs and 16 RA patients studied. Statistical analysis was performed with the Mann-
Whitney test. ***P < 0.0001. (C) Percentage of circulating early (Annexin V+/PI-) apoptotic T cells in all HDs and RA patients (9 Rs or 7 NRs to TNF-α
inhibitor therapy) studied. Statistical analysis was performed with the Mann-Whitney test. **P < 0.001; ***P < 0.0001. (D) Correlation between circulating
early apoptotic T cells and the sum of percentages of dextramer+CD8+ cells specific to a single epitope from the single R or NR (each symbol represents a
single patient) (Spearman correlation analysis) (left graph); correlation between circulating early apoptotic T cells and percentage of all dextramer+CD8+ cells
specific to a single epitope from R or NR (each symbol represents dextramer+CD8+ cells specific to a single AE) (right graph) (Spearman correlation
analysis). Analyses were performed at time 0 (before the start of therapy).
doi:10.1371/journal.pone.0128607.g003
Apoptosis-Induced T Cells Predict Response to TNF Inhibitor Therapy
PLOS ONE | DOI:10.1371/journal.pone.0128607 June 10, 2015 8 / 15
6D), strongly suggesting a relationship between these cells and the immunopathology and
chronic evolution of RA. Notably, the difference between Rs and NRs was also confirmed at
the level of the frequency of CD8+ T cells specific to a single peptide (S5 Fig).
Discussion
Here we demonstrate for the first time that frequency, multispecificity, and magnitude of
CD8+ T cells directed to AEs were significantly higher in RA patients compared with HDs, in-
dicating that they may contribute to RA pathogenesis, as well as previously demonstrated in
various immunopathology conditions [16,22]. Amazingly, the frequencies of AE-specific CD8+
T cells (as detected by dextramers) were significantly higher in Rs than in NRs at time 0 (before
Fig 4. Expression of activationmarkers by AE-specific CD8+ T cells in Rs and NRs (A-C). (A) Representative flow cytometry analysis of PD-1, HLA-DR,
and CD69 in AE-specific dextramer+CD8+ T cells from an R and an NR. (B) Percentage of AE-specific dextramer+CD8+ T cells expressing PD-1, HLA-DR, or
CD69 in all Rs and NRs studied. Statistical analysis was performed with the Mann-Whitney test. *P < 0.01; **P < 0.001; ns = not significant. (C) Correlation
between AE-specific dextramer+CD8+ T cells expressing PD-1 and total AE-specific dextramer+CD8+ T cells (Spearman correlation analysis). **P < 0.001.
Analyses were performed at time 0 (before the start of therapy).
doi:10.1371/journal.pone.0128607.g004
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the start of therapy), as indicated by the significant ROC sensitivity and specificity, and corre-
lated with the disease activity only in Rs. This, together with the finding that no clinical criteri-
on (including DAS28-ESR, DAS28-CRP, and ACPA) was capable of discriminating Rs and
NRs, suggests that the frequency of AE-specific CD8+ T cells represents a unique biomarker
predicting the response to TNF-α inhibitor therapy in RA patients. However, these T cell re-
sponses to AEs are unlikely to represent the first event that initiates RA pathology. Indeed, our
previous studies demonstrated that these responses require stimulation by apoptotic cells that
derive from preexisting activated T cells, such as the virus-specific T cells that are generated
during HIV or HCV infections [16,22]. We can envisage that in RA, the primary activated T
cells may be specific for disease-specific self-antigens (e.g., citrullinated epitopes) or even some
putative pathogen (possibly correlated with RA) that starts the immunological cascade leading
to RA, and, consequently, may provide the first boost of apoptotic antigens to AE-specific T
cells [15]. According to this scenario, the frequencies of AE-specific T cell responses were di-
rectly correlated with the percentage of circulating apoptotic T cells, suggesting that the emer-
gence of AE-specific CD8+ T cells is selectively related to the numbers of apoptotic T cells in
RA patients. AE-specific CD8+ T cells may strongly contribute to amplifying and sustaining
RA damage through a vicious cycle providing continuous waves of apoptotic antigens upon
performing their pro-inflammatory activity, as indicated by their correlation with the disease
Fig 5. AE-specific dextramer+CD8+ T cells specifically producing inflammatory cytokines inversely correlate with PD-1+dextramer+CD8+ T cells
(A-C). (A) Representative flow cytometry analyses of cells producing IL-17 or IFN-γ in dextramer+CD8+ T cells in response to a relevant AE pool (5 peptides).
(B) Percentage of cytokine-producing cells in dextramer+CD8+ T cells from Rs and NRs. Statistical analysis was performed with the Mann-Whitney test.
ns = not significant. (C) Correlation between cytokine-producing dextramer+CD8+ T cells and those expressing PD-1 (Spearman correlation analysis).
Analyses were performed at time 0 (before the start of therapy).
doi:10.1371/journal.pone.0128607.g005
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Fig 6. Time course analyses performed longitudinally throughout the follow-up in TNF-α inhibitor-treated patients (A-D). (A) Percentages of the
single AE-specific dextramer+CD8+ T cells determined before (t0) the start of TNF-α inhibitor therapy and after 1 month (t1) and 3 months (t3) from the start of
TNF-α inhibitor therapy in Rs and NRs (each symbol represents a single AE-specific dextramer+CD8+ T cell population). Statistical analysis was performed
with theWilcoxon matched pairs test. ***P < 0.0001; ns = not significant. The § symbol indicates the percentages of single AE-specific dextramer+CD8+ T
cells that were compared between Rs and NRs at the t1 (**P < 0.001). (B) Sum of percentages of the single-specific dextramer+CD8+ T cells in single R and
NR (each symbol represent a single patient). Statistical analysis was performed with theWilcoxon matched pairs test. ***P < 0.0001; ns = not significant.
The # symbol indicates the percentages of single AE-specific dextramer+CD8+ T cells that were compared between Rs and NRs at the t1 (**P < 0.001) (C)
Correlation between DAS28-ESR and percentage of AE-specific dextramer+CD8+ T cells in Rs (Spearman correlation analysis). (D) Parallel follow-up of AE-
specific dextramer+CD8+ T cell analyses and DAS28-ESR at t0, t1, and t3 from the start of TNF-α inhibitor therapy in Rs.
doi:10.1371/journal.pone.0128607.g006
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activity. The finding that the same responses are operative in various chronic infections (i.e.,
HIV or HCV [16,22]) or in autoimmune disorders, such as MS [23], suggests that they may
support a general mechanism of CIA in several immune-mediated diseases. By contrast, evi-
dence showing the inability of pancreatic β-cell apoptosis to provoke the development of domi-
nant AE-specific CD8+ T cell responses in type 1 diabetes in mice [28] could be attributed to
various non-mutually exclusive possibilities. One possibility is that apoptotic β cells are
CD40L- epithelial cells, which are generally unable to initiate efficient cross-priming of AE-
specific T cells (as CD40L+ apoptotic T cells do [22,23]). Another possibility is that the genera-
tion and maintenance of functional AE-specific responses likely require robust or long-term in-
flammatory responses that provide sustained apoptosis of activated T cells, particularly
occurring during human acute or chronic inflammatory diseases.
An important question that arises from our finding is why the frequencies of AE-specific
CD8+ T cells are significantly more elevated in Rs than in NRs before the start of therapy. An
attractive hypothesis is that AE-specific CD8+ T cells are more prone to PD-1-dependent ex-
haustion in NRs. This hypothesis is based on the following findings: (i) PD-1 expression in AE-
specific CD8+dextramer+ cells is significantly higher in NRs than in Rs, and correlates with the
decreased expansion of these cells; (ii) the percentage of AE-specific CD8+dextramer+ cells pro-
ducing cytokines in response to the relevant AE inversely correlates with the PD-1 expression.
This mechanism has been defined in various chronic viral and autoimmune diseases
[16,22,23]. Recently, a strict relationship between sustained type I IFN (IFN-I) signaling and
PD-1 overexpression on T cells, resulting in the establishment of a low level of CIA and de-
creased effector functions by virus-specific T cells, has been demonstrated in the mouse model
of persistent lymphocytic choriomeningitis virus infection [29,30]. With the relative differences
having been taken into account, the low level of CIA (likely attributed to upregulation of PD-1
expression) shown in NRs might be at a subthreshold level so as to be susceptible to TNF-α in-
hibitor therapy, which consequently might not restrain the chronic low-level disease progres-
sion. By contrast, Rs with a higher level of CIA would be more susceptible to TNF-α inhibitor
therapy, ultimately leading to control of disease activity. It will be of interest to verify whether a
genetic background predisposing to autoimmunity harbors variants that may foster this mech-
anism. Notably, we studied RA patients who were NRs to a previous therapy regime with meth-
otrexate in combination (or not) with other anti-inflammatory/immunosuppressive drugs (see
S1 Table). Further studies are required to determine if AE-specific CD8+ T cells distinguish dif-
ferent treatment-naïve patient populations (Rs or NRs) and/or if methotrexate or other immu-
nosuppressive drugs play a role in the development of these responses in patients with a
particular genetic signature that would contribute to establishing their profile.
Our previous data clearly demonstrated that caspase cleavage of apoptotic antigens is re-
quired to activate the related CD8+ T cells by cross-presentation, indicating that these auto-
reactive CD8+ T cells may contribute to immunopathology through the production of pro-
inflammatory cytokines upon cross-presentation of a huge number of apoptotic cells that infil-
trate inflamed tissues [31] rather than by the direct killing of target cells [15,16]. In addition,
other mechanisms may contribute to establishing chronic immunopathological processes. Re-
cently, active Epstein-Barr virus (EBV) infection has been demonstrated within ectopic lym-
phoid structures in the RA synovium in association with local differentiation of ACPA-reactive
B cells [32]. Moreover, several independent memory T cells (e.g., those that are specific to a
multitude of pathogens normally circulating in the lymphoid tissues), which are stimulated in
a bystander fashion, can be recruited in an inflammatory site where they can perform effector
functions [2,8,33,34].
However, irrespective of their possible pathogenic role, the finding that the total AE-specific
CD8+ T cells are significantly more elevated in Rs than in NRs to etanercept since time 0
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strongly suggests that these cells may have the potentiality for predicting patients who will (or
will not) benefit from TNF-α inhibitor therapy. This possibility appears to be clinically valuable
and appropriate for budgeting, thus allowing a preemptive submission of NRs to different boD-
MARDs. In this context, ongoing experiments validate the usage of AE-specific CD8+ T cells as
biomarkers predicting the response to a different TNF-α inhibitor, such as adalimumab. The
finding that the detection of CD8+ T cells specific to a single AE was sufficient to discriminate
Rs and NRs suggests that only one of them can be exploited as a potential predictive biomarker
of response to TNF-α inhibitor therapy. Further studies involving a larger study population are
needed to ascertain whether AE-specific CD8+ T cells could be exploited as a biomarker pre-
dicting response to alternative boDMARDs.
Supporting Information
S1 Table. Study population.
(DOCX)
S2 Table. HLA-A2 binding peptides derived from apoptotic cell-associated proteins (Pools
1–4).
(DOCX)
S3 Table. HLA-A2 binding peptides derived from apoptotic cell-associated proteins (Pools
5–8).
(DOCX)
S4 Table. HLA-A2 binding peptides derived from apoptotic cell-associated proteins (Pools
9–12).
(DOCX)
S1 Fig. DAS28 ESR score in R and NR. Patients were assessed for overall disease activity
using the DAS28, and categorized in Rs or NRs according to the EULAR criteria 6 months
after the start of treatment. An improvement of the DAS28>0.6 was considered a response to
therapy. Statistical was performed with Paired t test analysis. P<0.0001. ns = not significant.
(TIF)
S2 Fig. AE-specific CD8+ T cells predict RA patients who will (or will not) benefit from ada-
limumab therapy. Percentage of dextramer+CD8+ cells in 14 HDs, 2 Rs to adalimumab, and 4
NRs (each symbol represents the percentage of a single dextramer+CD8+ cell population). Sta-
tistical analysis was performed with the Mann-Whitney test. P< 0.001; P< 0.0001.
(TIF)
S3 Fig. Clinical criteria do not discriminate Rs and NRs. DAS28 ESR values (A), DAS28
CRP values (B), and RA duration (months) (C), before the start of TNF-inhibitor therapy, in R
and NR. Statistical analysis was performed with the Mann-Whitney test. ns = not significant.
(TIF)
S4 Fig. Follow-up of IFN-γ+ CD8+ T cells specific for AEs as detected by ELISPOT. Sum of
IFN-γ+ cell spots formed in response to AE pools, analyzed in R and NR at t0, t1, and t3 from
the start of anti-TNF-α therapy. Statistical analysis performed with Wilcoxon matched pairs
test P<0.01; P<0.001; P<0.0001. ns = not significant.
(TIF)
S5 Fig. Time course analyses of the dextramer+CD8+ T cells specific for the single AE. Per-
centage of dextramer+CD8+ T cells specific for the single AE indicated, in R and NR. Analyses
were performed at t0, t1, and t3 from the start of TNF-α inhibitor therapy. Statistical analysis
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was performed with Wilcoxon matched pairs test P<0.01; P<0.001; P<0.0001.
ns = not significant.
(TIF)
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